Your browser doesn't support javascript.
loading
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.
Bespalov, Anton; Steckler, Thomas; Altevogt, Bruce; Koustova, Elena; Skolnick, Phil; Deaver, Daniel; Millan, Mark J; Bastlund, Jesper F; Doller, Dario; Witkin, Jeffrey; Moser, Paul; O'Donnell, Patricio; Ebert, Ulrich; Geyer, Mark A; Prinssen, Eric; Ballard, Theresa; Macleod, Malcolm.
Afiliación
  • Bespalov A; Neuroscience Research, AbbVie, 6706 Ludwigshafen, Germany. Present address: Partnership for Assessment and Accreditation of Scientific Practice, Am Aukopf 14/1, D-69118 Heidelberg, Germany and Institute of Pharmacology, Pavlov Medical University, 197022 St Petersburg, Russia.
  • Steckler T; Janssen Research and Development, B-2340 Beerse, Belgium.
  • Altevogt B; Global Policy and International Public Affairs, Pfizer, New York, 10017 New York, USA.
  • Koustova E; National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Skolnick P; National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland 20892, USA.
  • Deaver D; Non-Clinical Research and Development, Alkermes, Waltham, Massachusetts 02451, USA.
  • Millan MJ; Institut de Recherche Servier, 78290 Croissy sur Seine, France.
  • Bastlund JF; Neuroscience Research, H. Lundbeck A/S, Copenhagen, 2500 Valby, Denmark.
  • Doller D; Discovery Chemistry &DMPK; Lundbeck Research USA, Paramus, New Jersey 07652, USA. Present address: Concert Pharmaceuticals, Inc., 99 Hayden Avenue, Lexington, Massachusetts 02421, USA.
  • Witkin J; Neuroscience Discovery Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
  • Moser P; Pierre Fabre Research Institute, 81106 Castres, France. Present address: BIAL-Portela &Ca S.A., Avenida da Siderurgia Nacional, 4745-457 São Mamede do Coronado, Portugal.
  • O'Donnell P; Neuroscience and Pain Research Unit, Pfizer, Cambridge, Massachusetts 02139, USA.
  • Ebert U; Boehringer Ingelheim Pharma, 55218 Ingelheim am Rhein, Germany.
  • Geyer MA; University of California San Diego, La Jolla, California 92093, USA.
  • Prinssen E; Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Ballard T; Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
  • Macleod M; Edinburgh University, Old College, South Bridge, Edinburgh EH8 9YL, UK.
Nat Rev Drug Discov ; 15(7): 516, 2016 Jul.
Article en En | MEDLINE | ID: mdl-27312728
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Enfermedades del Sistema Nervioso Central / Ensayos Clínicos como Asunto / Evaluación Preclínica de Medicamentos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Rev Drug Discov Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Rusia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Enfermedades del Sistema Nervioso Central / Ensayos Clínicos como Asunto / Evaluación Preclínica de Medicamentos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Rev Drug Discov Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Rusia